Regeneron Pharmaceuticals, Inc. (0R2M.L)
- Investor's Business Daily
Swing Trading Regeneron Stock Shows How To Bob And Weave
What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come. Here's how.
- Zacks
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
- GlobeNewswire
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the European Union (EU) Approval represents the sixth approved indication for Dupixent in the EU and seventh
